Shopping Cart
- Remove All
Your shopping cart is currently empty
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models [1].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $162 | In Stock | |
| 5 mg | $322 | In Stock | |
| 10 mg | $579 | In Stock | |
| 25 mg | $1,180 | In Stock | |
| 50 mg | $1,950 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $645 | In Stock |
| Description | RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models [1]. |
| In vivo | RMC-6291 (200mg/kg, orally, once daily, for 60 days) significantly inhibits tumor growth and induces immune memory in mouse tumor models. [1] |
| Synonyms | RMC6291, RMC 6291, 2775304-30-6 |
| Molecular Weight | 1012.26 |
| Formula | C55H78FN9O8 |
| Cas No. | 2641998-63-0 |
| Smiles | O=C(C#CC(N(C)C)(C)C)N1CCC(F)(C(=O)N(C)C(C(=O)NC2C(=O)N3NC(C(=O)OCC(C)(C)CC=4C5=CC(=CC=C5N(C4C=6C=CC=NC6C(OC)C)CC)N7CCOC(C7)C2)CCC3)C(C)C)CC1 |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (79.03 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.